PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol (CBD) prodrug and the second therapeutic candidate developed from PureTech’s Glyph™ platform to be advanced toward the clinic. Clinical studies of LYT-310 are expected to begin in Q4 of 2023. A CBD-based product has received regulatory approval in the United States and Europe to treat seizures resulting from certain rare conditions, but it requires a large volume of a sesame oil-based formulation, which limits its use in broader indications and age groups. PureTech’s LYT-310 is designed to greatly expand the therapeutic application and potential of CBD by: enabling oral administration in a capsule; expanding the use of CBD into a broad range of therapeutic areas and patient populations (such as adolescents and adults) where higher doses are required to achieve a therapeutic effect; potentially improving safety and reducing gastrointestinal (GI) tract side effects that are associated with the currently approved CBD-based treatment by reducing GI and liver exposure; and allowing for a readily scalable, consistent product in a cost-effective manner. “The nomination of LYT-310 is an exciting expansion of PureTech’s Glyph technology,” said Daniel Bonner, Ph.D., Vice President at PureTech Health. “The data generated to date with LYT-310 further demonstrate our ability to apply the Glyph technology to an array of molecules to enable or greatly enhance oral bioavailability. This approach allows us to unlock the therapeutic potential of a range of molecules with validated efficacy whose development has been limited by first pass metabolism by the liver.” In multiple preclinical models, including large animal and non-human primate, LYT-310 has demonstrated a three to fourfold increase in oral exposure vs. unmodified CBD in a fasted state. This has the potential to translate into improved safety and reduced side effects. Lymphatic transport has also been confirmed in preclinical models, with up to 30% of LYT-310 entering the lymphatics, compared to 5% for unmodified CBD – which further supports the novel Glyph mechanism of enhancing bioavailability. The first candidate from the Glyph technology platform, LYT-300 (oral allopregnanolone), is currently being evaluated in a multi-part Phase 1 trial designed to demonstrate oral bioavailability, evaluate safety and tolerability across a range of doses, and to inform dose selection moving forward. The first objective was achieved earlier this year, and LYT-300 demonstrated oral bioavailability of allopregnanolone approximately ninefold greater than that of orally administered allopregnanolone, based on previously published data. The Phase 1 clinical trial is expected to be completed by the end of 2022, and – based on the data – a Phase 1b/2a clinical trial is planned to initiate in 2023. About the GlyphTM Platform Glyph is PureTech’s synthetic lymphatic-targeting chemistry platform which is designed to employ the lymphatic system’s natural lipid absorption and transport process
http://dlvr.it/SdcdC8

Growth Opportunities in Nanomaterials and Nanocoatings: Multi-Walled Carbon Nanotubes Show Great Promise – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Nanomaterials and Nanocoatings" report has been added to ResearchAndMarkets.com's offering. This issue of the Nanotechnology Opportunity Engine covers growth opportunities in nanomaterials and nanocoatings. The TOE focuses on multi-walled carbon nanotubes that promise enhanced dispersibility in a wide range of organic solvents, a silver nanoparticle ink that delivers low electrical resistance and temperature sintering, an electrochemical technique for producing low-cost carbon nanotubes from carbon dioxide, and a water-based multilayer nanocoating that promises desired mechanical properties in textile substrates. The TOE also covers an invisible fluorescent nano-ink-based identifier/tag, a nanomaterial-based cost-effective water purification unit, a recyclable and durable dielectric nanolayer film, and a nano emulsion technology for manufacture of cannabidiol-based beverages. The Nanotechnology Opportunity Engine provides intelligence on technologies, products, processes, applications, and strategic insights on nanotechnology-related innovations and their impact across various industries. Technology focus areas include nanocatalysts, antimicrobials, nanocellulose, and nanoplatelets. The Chemicals and Advanced Materials cluster tracks research and innovation trends and developments across specialty chemicals, plastics, polymers, chemicals, bio-chemicals, metals, coatings, thinfilms, surface treatments, composites, alloys, oil and gas, fuel additives, fibers, and several other related technologies and its impact and application across industries. Key Topics Covered: Technology Advances in Nanomaterials and Nanocoatings Nanomaterials Offering An Alternative to Rare Earth Metals and Delivering High Conductivity and Transparency Environmental and Energy Benefits Driving Technological Advancement Meta Materials Inc. - Investor Dashboard Multi-Walled Carbon Nanotubes Promising Enhanced Dispersibility in a Wide Range of Organic Solvents Developed Mwnt Can Potentially Reduce Processing Time and Cost in Industrial Applications Glonatech - Investor Dashboard Silver Nanoparticle Ink Delivering Low Electrical Resistance and Temperature Sintering Nanoparticle Based Ink Offering An Alternative to Commercial Silver Inks for Screen Printing and Inkjet Printing Daicel Corporation - Investor Dashboard Electrochemical Technique Promising to Produce Low-Cost Carbon Nanotubes from Carbon Dioxide Electrochemical Process Offering a Cost-Effective and Less Energy-Intensive Process for Converting Co2 to Cnt Skynano - Investor Dashboard Fullerite Gel Offers Superhydrophobic Surfaces Superhydrophobic Nanomaterials with Easy Fabrication and Processing from Ucf Water-Based Multilayer Nanocoating Promising Desired Mechanical Properties in Textile Substrates Nanocoating Offering Multi-Protective Characteristics for Textiles Invisible Fluorescent Nano-Ink-Based Identifier/Tag Arylla's Invisible Identifier/Tag for Seamless Integration with Product Labels and Software for Digital Tracking Arylla - Investor Dashboard Nanomaterial-Based Cost-Effective Water Purification Unit Nanomembrane Filtration Technology for Rapidly Purifying Sea and Brackish Water in Less Than 5 Minutes Nanoseen - Investor Dashboard Recyclable, Durable Dielectric Nanolayer Film Sustainable Yet Highly Effective Dielectric Film That is in Par with Other Competing Technologies Peak Nanosystems - Investor Dashboard Nanoemulsion Technology for Manufacturing Cbd-Basedbeverage Nanoemulsion Technology Can be Used for Manufacture of Various Cannabis-Based Products Hemprise - Investor Dashboard
http://dlvr.it/Sdc7MP

Moonstone Bank Issues Statement Regarding Alameda Research Ventures, LLC

FARMINGTON, Wash.--(BUSINESS WIRE)--Farmington State Bank d.b.a Moonstone Bank today issued a statement addressing questions and correcting inaccurate and unsupported allegations around an investment in FBH Corporation, the bank’s holding company, made by Alameda Research Ventures, LLC in January 2022. Moonstone Bank (Farmington State Bank) is a 135-year-old bank that, since its 2020 acquisition by FBH Corporation, embraced an innovative startup business model, with the goal to serve new customers in underserved industries, such as digital assets and hemp/cannabis businesses. The new model leverages management and technology, built and selected for purpose, to safely and soundly support these innovative businesses and consumers. Throughout our history and throughout the recent process of transforming our business model, we have remained in close communication with our regulators and have built robust processes, programs, and controls to ensure all our activities comply with all applicable laws and regulations. In January this year, as a result of a capital raise effort to support our further development, we received an investment from a company that at the time had a pristine reputation and was a darling of the financial markets. Unfortunately, the unexpected collapse of this company negatively impacted countless individual investors, investment firms, vendors, counterparties and unfairly affected Farmington State Bank d.b.a Moonstone Bank’s reputation as well. Alameda has a non-controlling interest in Moonstone, with no board membership and no involvement with management. As every startup, we sought to raise capital to fund our business plan and growth. In January 2022, Alameda Research Ventures, LLC invested $11.5 million in Moonstone (through FBH, Moonstone’s holding company) for a non-controlling minority common-share interest (under 10%). Alameda has remained a passive investor, with no board membership and with no involvement in management. As it appears now from documents made public, Alameda Research/FTX deployed more than $2 billion in venture capital across 179 investments, in regard of which the investment in our company represents less than 0.6%. Moonstone’s valuation was consistent with other similar technology Banks and Trust Banks startups at the time. Because of Moonstone’s technology and data first strategy, solving for a known gap in banking, and the large potential it offers, the bank was seen as a financial technology bank and valued as such, with a multiple typical for similar entities. Other similar technology driven Bank and Trust Bank startups achieved significantly higher valuations during the same period, including multiple pre-launch, pre-revenue start-ups. Jean Chalopin, individually and without any connection to Deltec Bank acquired Farmington State Bank (Moonstone) following all appropriate regulatory requirements. In mid-summer 2018, Mr. Chalopin individually and without any connection to or without any involvement to Deltec International Group and its subsidiaries, began searching to acquire a bank in the United States to develop a new model of banking in which he strongly believes, to capitalize on the convergence of technologies and regulations to ensure needed and reliable banking services to customers. Mr. Chalopin followed standard procedures for acquiring a United States bank pursuant to
http://dlvr.it/SdZkdG

High Tide Launches Exclusive Paid Membership Program: “Cabana Elite”

CALGARY, Alberta--(BUSINESS WIRE)--High Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets, is pleased to announce the launch of Cabana Elite (“ELITE”), an optional paid membership upgrade for Cabana Club members. Starting today, customers can sign up for ELITE in-store and online at www.cannacabana.com. The Company expects that ELITE will extend the Cabana Club membership program, attract new customers and instill even greater customer loyalty. The Company anticipates that further discounts, benefits and promotions will be regularly added to ELITE. The table below outlines the various perks and benefits available to ELITE members:   Cabana Club ELITE2 UNBEATABLE prices on cannabis3 √ √ Up to 80% off accessories, everyday √ √ 25% off accessory coupon   √ Triple entries into the 420 Car Giveaway, featuring a TESLA Model Y valued at over C$100,000   √ Exclusive and limited edition ELITE branded accessories   √ ELITE Flash Sales   √ Birthday bags   √ Cabana Cannabis Co. discount   √ Discounts on High Tide’s leading e-commerce accessory platforms   √ 5000+ retail and restaurant deals   √ Tours, events and tickets   √ 50% off delivery fee   √ “I am delighted to finally announce the launch of ELITE, the next evolution in our innovative discount club model and a huge milestone for High Tide. The continuous innovation from our team has positioned us as a top-performing Canadian cannabis company, and ELITE is the natural result of this success. By leveraging the strengths of our diversified cannabis ecosystem, we are providing additional value to ELITE members by offering discounts on High Tide’s global online consumption accessories platforms. We see this as a big step towards building our loyalty program into a global cannabis community as we continue to convert price-conscious consumers from the illicit market into our legal cannabis ecosystem,” said Raj Grover, President and Chief Executive Officer of High Tide. “Our goal is to sign up as many Cabana Club members to ELITE as possible within the first year, following which we anticipate an even greater financial
http://dlvr.it/SdY0Kc

FSD Pharma Announces Changes to the Board of Directors

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is pleased to announce the appointments of Dr. Lakshmi P. Kotra and Mr. Joseph L. Romano to its Board of Directors, effective November 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the Board of Directors. Dr. Lakshmi Kotra received his Ph.D. in Pharmacy (Medicinal Chemistry) from the University of Georgia under Prof. David Chu’s supervision, and completed postdoctoral training at Wayne State University under Prof. Shahriar Mobashery’s supervision. He joined the Faculty of Pharmacy, University of Toronto in 2000, and University Health Network in 2006, where he led a research group and drug discovery program with multiple portfolios. An academic entrepreneur, Dr. Kotra has contributed to a number of important drug discovery and development projects, including metabolic disorders, neurodegenerative and immunological disorders, anti-HIV drugs, antibacterials, and antimalarials. He has authored/co-authored over 130 publications and delivered over 140 scientific talks internationally. Dr. Kotra is the recipient of several awards for his accomplishments, including the Julia Levy Award in 2021 from the Society of Chemical Industry (SCI) Canada in recognition of his substantial contribution to the successful commercialization of innovation in Canada in the field of biomedical science and engineering. In addition to Lucid Psycheceuticals Inc. (“Lucid”), he co-founded WinSanTor Biosciences, a San Diego, CA-based company developing treatments for peripheral neuropathies, and CannScience Innovations focused on medical cannabis and cannabinoids. Dr. Kotra transcends early and clinical development incorporating commercial and regulatory vision for efficient drug development and commercialization with solid leadership. Dr. Kotra has been serving the Company as Chief Executive Officer of its wholly owned subsidiary, Lucid, upon completion of the Company’s acquisition of Lucid in September 2021. Mr. Romano is the founding member of Romano Law Firm. He has dedicated his law career to helping victims of serious personal injury and motor vehicle accidents. A graduate of Osgoode Hall Law School, Mr. Romano has appeared at all levels of court in Ontario, Canada with success. “On behalf of FSD, I would like to thank Mr. Cugliari for his contributions to the Board. We wish him all the best in his future endeavours. We also welcome Dr. Kotra and Mr. Romano to the Board of Directors. Their combined wealth of knowledge and experience we believe will be valuable,” said Anthony Durkacz, Founder, Interim CEO & Executive Co-Chairman of the Company. About FSD Pharma FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, a proprietary ultra-micronized PEA formulation, for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound
http://dlvr.it/SdWflN

Flora Growth Reports Third Quarter 2022 Financial Results

FORT LAUDERDALE, Fla. & TORONTO--(BUSINESS WIRE)--Flora Growth Corp. (NASDAQ: FLGC) (“Flora'' or the “Company”), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, reported today its financial and operating results for the third quarter and nine months ended September 30, 2022. All financial information is provided in U.S. dollars unless indicated otherwise. “The third quarter of 2022 was another exciting quarter for Flora as we continued to lay the foundation of our business for the long-term,” said Luis Merchan, Chairman a CEO of Flora Growth. “During the quarter, we exported products to several new markets, including distribution of our Colombian grown high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate to the United States. Our global distribution network, coupled with our high-quality Colombian flower and derivatives, leave Flora well positioned to capitalize on the evolving global cannabis landscape.” “Subsequent to the quarter, we signed a definitive agreement to acquire Franchise Global Health, a pharmaceutical and medical cannabis distributor with principal operations in Germany. This transformative deal would connect our Colombian commercial infrastructure and product portfolio to the German and EU cannabis markets, allowing Flora to significantly increase its international footprint. “As we look ahead to the end of the year, we expect to finalize the transaction and solidify our presence in the European cannabis market. With our industry leading production costs and expanding global footprint, we believe our business is well positioned to accelerate growth into 2023 and beyond.” 3Q2022 Financial Highlights Total revenue for the quarter was $10.8 million, an increase of 414% year over year, driven by Flora’s House of Brands division, which includes the acquisitions of JustCBD and Vessel. Gross profit increased to approximately $5.0 million, up approximately 703% year over year. Gross margin in the quarter improved from 29.6% to 46.2% year over year, and demonstrated a gradual improvement from 43.9% during 1H2022. Net loss was approximately $7.4 million compared to a net loss of $3.6 million in 3Q 2021. Net loss margins reduced year over year, year to date, and in comparison to 1H2022. Adjusted EBITDA (a non-IFRS measure defined below) was $(3.9) million compared to $(3.1) million in 3Q 2021. Adjusted EBITDA margin improved significantly from -150.1 % in 3Q2021 to -36.5 % in 3Q2022. For a reconciliation of these non-IFRS financial measures to the most directly comparable IFRS financial measures, please see Table 4 under "Reconciliation of IFRS to non-IFRS financial results" included at the end of this release. As of September 30, 2022, the Company had approximately $5.9 million in cash compared to $37.6 million as of December 31, 2021. The decrease was primarily due to cash paid for the acquisition of JustCBD, as well as higher operating expenses related to investments in headcount, sales and marketing and one-time expenses associated with Cosechemos operations and the Flora Lab expansion. 2022 Outlook
http://dlvr.it/SdVSP0

Cannabis Extraction Global Markets Report 2022-2027 with Focus on Extraction Equipment and Services – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cannabis Extraction: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report studies the global market for cannabis extraction equipment and services using 2021 as a base year and provides estimates for each year of the forecast period, 2022-2027, with projections for CAGR. The scope of this report is limited and covers global markets for cannabis extraction equipment and services only. The market is divided by equipment, services, methods and region. Projected and forecasted market size estimates are constant U.S. dollars that have not been adjusted for inflation. A cannabis extract is a concentration made from cannabis that has been dissolved in a solvent. Although the terms 'extract' and 'concentrate' are commonly used interchangeably, extracts are not all concentrates, but concentrates are all extracts. While concentrates can be generated using a variety of mechanical techniques as well as the use of a solvent, extracts are the only type of concentrate that requires the use of a solvent. Butane, propane, ethanol and supercritical carbon dioxide (CO2) are the most frequent solvents used to generate a cannabis extract. The wide range of products known as cannabis extracts contain more cannabinoids than the actual cannabis plant. When consumed, cannabinoids, which are chemical components of cannabis, have an impact on both the body and mind. The most well-known cannabinoid, THC (tetrahydrocannabinol), is the one that results in euphoria and intoxication (or high). Although more research is required, the non-psychoactive cannabinoid CBD (cannabidiol) has some potential as a medicine. Cannabis extracts can contain a wide range of THC and CBD concentrations. While some extracts have a THC content of up to 99%, others are mostly CBD with very little THC. This report provides market insights into the global cannabis extraction market, focusing on the U.S., Europe, Asia and the top cannabis extraction companies in those countries. It provides information, including market size, expected growth rates, market drivers, restraints, and other trends and developments. This report also discusses the major players in each regional market for cannabis extraction. It explains the foremost market drivers of the global cannabis extraction market, current trends within the industry, and the regional dynamics of the cannabis extraction market. The report concludes with detailed profiles of major international vendors in the cannabis extraction industry. Descriptive company profiles of the major cannabis extraction companies, including Aptia Engineering, Danaher Corp., Eurofins Scientific, Neptune Wellness Solutions, PerkinElmer Inc., Root Sciences and Sage Analytics Report Includes Analyses of the global market trends, with historic market revenue for 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027 Estimation of the actual market size for cannabis extraction industry, market forecast, and corresponding market share analysis by equipment, services, extraction method, and geographic region Coverage of the technological, economic and business considerations of the cannabis extraction market with analyses and forecasts provided for global markets Discussion of current and future market potential
http://dlvr.it/SdTyx0

Global Cannabidiol Market Report 2022: Growing Acceptance and Use of Products Due to Government Approvals Drives Sector – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Cannabidiol Market (2022-2027) by Type, Distribution Channel, End-User, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Cannabidiol Market is estimated to be USD 3.76 Bn in 2022 and is expected to reach USD 8.15 Bn by 2027, growing at a CAGR of 16.72% Market Dynamics Drivers Growing Acceptance and Use of Products Due to Government Approvals Rising Demand from Medical and Pharmaceutical Industry Increasing Awareness of Healing Properties of Cannabidiol Restraints Risk of Side-Effects Such as Dry Mouth, Diarrhea, Reduced Appetite Legal Constraint on Sales of CBD in Some Countries Opportunities Increasing Customer Inclination Towards Natural or Herbal Remedies/Products Boosting Product Sales Though Alliances With Health and Wellness Retailers Challenges Lack of Awareness and Standardization in Many Developing Markets     Market Segmentations The Global Cannabidiol Market is segmented based on Type, Distribution Channel, End-User, and Geography. By Type, the market is classified into Hemp and Marijuana. By Distribution Channel, the market is classified into B2B and B2C. By End-User, the market is classified into Medical, Personal Use, Pharmaceuticals, and Wellness. By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific. Company Profiles The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are ABcann Medicinals, Inc., Aphria, Inc, Aurora Cannabis, Cannoid, LLC, Canopy Growth Corp., etc. Countries Studied America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas) Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe) Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA) Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific) Competitive Quadrant The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Ansoff Analysis The report presents a detailed Ansoff matrix analysis for the Global Cannabidiol Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The
http://dlvr.it/SdK46P

Rosen Introduces Legislation to Ensure Cannabis Small Businesses Can Access SBA Loans and Programs Available to Other Small Business

WASHINGTON, DC — Yesterday, U.S. Senator Jacky Rosen (D-NV), a member of the Senate Committee on Small Business and Entrepreneurship, introduced the Fair Access for Cannabis Small Business Act to ensure that legally operating cannabis small businesses have access to loans and programs provided by the Small Business Administration (SBA). Currently, the SBA excludes all small businesses with Read the full article...
http://dlvr.it/Sd8Lxj

Commission Reminds Licensees of Agency’s Authority

OLCC takes action on THC lab shopping OREGON: Members of the Oregon Liquor and Cannabis Commission (OLCC) have a message for OLCC licensees – if you flaunt the rules and test our authority we’re going to come down on you, even if we think your complaint has merit. At its regularly scheduled monthly meeting on Read the full article...
http://dlvr.it/Sd7zX3

Global Cannabidiol (CBD) Strategic Business Report 2022: Market to Reach $13.4 Billion by 2027 – U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 19.8% CAGR – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cannabidiol: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Cannabidiol Market to Reach $13.4 Billion by 2027 In the changed post COVID-19 business landscape, the global market for Cannabidiol estimated at US$5 Billion in the year 2020, is projected to reach a revised size of US$13.4 Billion by 2027, growing at a CAGR of 15.1% over the analysis period 2020-2027. Hemp, one of the segments analyzed in the report, is projected to record 16.4% CAGR and reach US$8.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Marijuana segment is readjusted to a revised 12.8% CAGR for the next 7-year period. The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 19.8% CAGR The Cannabidiol market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$3 Billion by the year 2027 trailing a CAGR of 20.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.1% and 13.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR. What's New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and Research Platform Complimentary updates for one year Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Cannabidiol - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) 2. FOCUS ON SELECT PLAYERS (Total 47 Featured) ABcann Medicinals, Inc. Aphria, Inc Aurora Cannabis Canopy Growth Corporation CBD LION CBDfxBota CBDistillery cbdMD GW Pharmaceuticals, plc Kazmira Maricann, Inc. (Wayland Group Corporation) Medixcbd Medterra NuLeaf Naturals Organigram Holding, Inc. The CBD Company The Cronos Group Tikun Olam Tilray 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE III. REGIONAL MARKET ANALYSIS UNITED STATES Cannabidiol Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) CANADA JAPAN Cannabidiol Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) CHINA Cannabidiol Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) EUROPE
http://dlvr.it/Sd71jM

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, has been invited to present late-breaking data at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England. Late-breaking abstract entitled “
http://dlvr.it/ScxC2C

Programmatic Advertising Global Market Research Report 2022 Featuring Major Players – Adobe, AdReady, AdRoll, Magnite, & Baidu – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Programmatic Advertising Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global programmatic advertising market is expected to grow from $6.06 billion in 2021 to $7.38 billion in 2022 at a compound annual growth rate (CAGR) of 21.77%. The programmatic advertising market is expected to reach $18.42 billion in 2026 at a compound annual growth rate (CAGR) of 25.67%. The main types of media utilizing programmatic advertising are audio ads, DOOH, digital display, social ads and video ads. The audio ads refers to the automated process of buying, selling, and delivery of audio ads. The audio ads include digital radio, podcasts, audio articles, and streaming music services. These ads are viewed on mobile and desktop and for SMBs (small and medium-sized businesses) and large enterprises. Programmatic advertising end users are education, media and entertainment, retail and travel. North America was the largest region in the programmatic advertising market in 2021. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmatic advertising market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The increasing growth of the mobile industry is expected to significantly contribute to the growth of the programmatic advertising market. The increasing population, advancing technologies, and increased use of the internet are contributing to the development of the mobile industry. Internet and the use of mobiles have become the universal source of information for millions of people, at home, at school, and at work. The increasing growth of the mobile market coupled with the advancements will enhance the programmatic advertising as it enables automation, improve data quality, and structure all data in a better and smarter software application for targeting the appropriate user at the lowest operational cost. For instance, according to The Mobile Economy 2022 report published in February 2022 by a UK-based industry organization representing the interests of global mobile network operators GSM Association, globally, the number of mobile internet subscribers is projected to reach 5 billion by 2025 from 4.2 billion in 2021, representing 60% of the population by 2025 from 53% in 2021. Therefore, the increasing growth of the mobile market will drive the growth of the programmatic advertising market. Technological advancement is a key trend gaining popularity in the programmatic advertising market. The market is witnessing the implementation of next-generation technologies into programmatic advertising such as data science in addition to AI (artificial intelligence) & ML (machine learning), text API (application programming interface), CRM (customer relationship management) software, and others. These advanced programmatic advertising solutions offer end-to-end engagement and better optimization in addition to automation. Major companies operating in the programmatic advertising market are focused on providing technologically advanced programmatic advertising solutions to acquire more customers and strengthen their market position. For instance, PandoLogic, a US-based software company, offers pandoIQ, the most advanced programmatic job advertising solution for enterprise recruitment. The pandoIQ platform uses algorithms built
http://dlvr.it/Scwj0s

Global Hemp CBD Market Report 2022: Rise in the Demand for Hemp CBD from Various Industries Such As Food & Beverage, Personal Care and Cosmetics Drives Growth – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Hemp CBD Market (2022-2027) by Distribution Channel, End-Users, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Hemp CBD Market is estimated to be USD 3.3 Bn in 2022 and is expected to reach USD 7.6 Bn by 2027, growing at a CAGR of 18.15% Market Dynamics Drivers Rise in the Demand for Hemp CBD from Various Industries Such As Food & Beverage, Personal Care and Cosmetics Increasing Use of CBD-Derived Products in Pharmaceutical and Wellness Products Changing Consumer Opinion and Increasing Awareness about the Health Benefits of Cannabidiol Restraints Lack of Proper Planting & Harvesting Equipment Increasing Legalization on CBD Products Due to Various Health Side Effects Opportunities Lack of Proper Planting & Harvesting Equipment Increasing Legalization on CBD Products Due to Various Health Side Effects Challenges Stringent Transportation Regulations and Increased Warehousing Cost Market Segmentations The Global Hemp CBD Market is segmented based on Distribution Channel, End-Users, and Geography. By Distribution Channel, the market is classified into B2B and B2C. By End-Users, the market is classified into Medical, Personal Use, Pharmaceutical, and Wellness. By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific. Competitive Quadrant The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Ansoff Analysis The report presents a detailed Ansoff matrix analysis for the Global Hemp CBD Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach. The analyst analyses the Global Hemp CBD Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position. Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth. Key Topics Covered: 1 Report Description 2 Research Methodology 3 Executive Summary 4 Market Dynamics 5 Market Analysis 6 Global Hemp CBD Market, By Distribution Channel 7 Global Hemp CBD Market, By End-Users 8 Americas' Hemp CBD Market 9 Europe's Hemp CBD Market 10 Middle East and Africa's Hemp CBD Market
http://dlvr.it/Scq36T

Wellbeing Subsidiary KGK Science Announces Successful Delivery of CBD and THC Through the Skin of Healthy Volunteers

VANCOUVER, British Columbia--(BUSINESS WIRE)--Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that its wholly owned subsidiary KGK Science Inc. (“KGK”), completed an open label study, where Gefion Canada (“Gefion”) GT4 technology was used to successfully deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volunteers in the form of a topical cream applied to the skin. Gefion GT4 technology uses novel penetrating agents to transport CBD and THC through the skin and directly into the blood. Transdermal delivery of topically-applied cannabinoids can be difficult and prior to this study, published research demonstrating successful topical delivery did not exist. The Gefion Canada study, published in Advances in Therapy, showed for the first time that CBD and THC were successfully transported into the blood stream following application to the skin. Gefion GT4 technology may provide lower, more steady-state cannabinoid concentrations that minimize psychoactive effects in participants. These findings present a potential benefit in the treatment of chronic conditions over longer periods of time, or in the treatment of diseases where high concentrations of cannabinoids are needed in relation to the body weight of vulnerable populations such as pediatrics. Importantly, CBD and THC delivery in this study was found to be safe and well tolerated by all participants. None of the volunteers experienced any intoxicating effects. Topical cannabis may provide the benefit of extended cannabinoid delivery without the worry of intoxication, suggesting it may be beneficial for certain lifestyles and therapeutic indications. However, more research is needed. “This study represents an important step forward in cannabis research. This study opens the door for future double-blind, placebo-controlled trials to further investigate topical cannabis delivery,” says Dr. Erin D. Lewis, Scientific Director at KGK Science. ABOUT GEFION Gefion is a specialty pharmaceutical company whose mission is to utilize its technological, regulatory and commercial advantages to market cannabinoid prescription products in the United States, Canada and Europe focusing on established markets with predicate products and insurance reimbursement. It is developing GT4 CBD for the treatment of epilepsy in children. ABOUT KGK SCIENCE Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com. ABOUT WELLBEING DIGITAL SCIENCES
http://dlvr.it/SclVQg

Global Biocomposites Market Report to 2027 – Rising Demand for Durable and Environmentally Friendly Manufacturing Materials is Driving Growth – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Biocomposites Market Size, Trends and Growth Opportunity, By Type, Process, Fiber Type, Product, End user, By Region and Forecast to 2027." report has been added to ResearchAndMarkets.com's offering. The Global Biocomposites Market was valued at US$24.3 billion in 2021 and it is expected to reach at US$80.2 billion in 2027 at a CAGR of 15.59% during forecast period 2022-2027. Companies Mentioned UPM (Finland) Trex Company Inc. (U.S.) Fiberon (U.S.) Flexform SpA (U.S.) UFP Industries Inc. (U.S.) Meshlin Composites ZRT (Hungary) Tecnaro GmbH (Germany) Anhui Guofeng Wood-Plastic Composite Co. Ltd. (China) B.COMPOSITES PVT.LTD. (India) Green Dot Corporation (U.S.) Natural fibres including hemp, wood and paper waste, jute, and flax are combined with a polymer matrix to create biocomposites. From construction to packing to autos, these composites have a wide range of uses. Environmentally friendly biocomposites have become well-liked building materials. Additionally, throughout the projected period, tight environmental regulations are anticipated to support the expansion of the biocomposite market. Market Drivers The aerospace and defence industries' need for biocomposite will result in exceptionally high demand for the bio-based product. The current increase in the usage of biocomposite in the aerospace industry for the production of aircraft equipment, which demands ultra-advanced composites that can maintain the product, is anticipated to be the primary driver of the market for biocomposites. Furthermore, the main factor anticipated to propel the growth rate of the biocomposites market is the rise in demand for durable and environmentally friendly manufacturing materials. Market Restraints The market's expansion may be constrained by the high availability of biocomposites' competitors on the market, such as carbon fibre and glass fibres. Compared to carbon fibre and glass fibre composites, biocomposites are less durable. The key factor that impeding the growth of the global biocomposites market. Impact of COVID-19 on Biocomposites Market The market for biocomposites was negatively impacted by the coronavirus outbreak. Because of this epidemic, the government has enacted strict international regulations, which have negatively impacted the development of the biocomposites market. Due to the falling demand for biocomposites internationally, the major end markets for these materials, including the automotive, building, aerospace, and other sectors, have likewise stopped producing them. Additionally, the majority of the market's raw material suppliers for biocomposites have stopped doing business, and the main suppliers have shifted their focus to pandemic relief. Market Segmentation By Type Structural Non-Structural By Process Compression Molding Injection Molding Resin Transfer Molding Others By Product Hybrid Green By Fiber Type Fiber Non-Wood Fiber By End User Building And Construction Transportation Consumer Goods Key Question Addressed by the Report
http://dlvr.it/Scbn3C

Lyocell Fibers Global Market Report 2022: Minimal Environmental Impact Driving Adoption – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Lyocell Fibers Market By Type, By Application: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering. The global lyocell fibers market was valued at $1.3 billion in 2021, and is projected to reach $2.7 billion by 2031, growing at a CAGR of 8.2% from 2022 to 2031. Lyocell fibers are used in woven and nonwoven items such as household textiles, surgical devices, and baby diapers as they are shrink resistant, eco-friendly, biodegradable, and durable. Lyocell fibers have been shown to have enhanced antibacterial activity against different bacteria and fungus indicating promise use in medicinal or sanitary products. The growth of the global lyocell fibers market is majorly attributed to its wide applications in various industries such as apparel, home textile, medical & hygiene, filtration, footwear, and others. Lyocell fibers is used across many applications such as apparel, home textiles, medical and hygiene, filtration and others. Lyocell fiber is a rayon fabric made by dissolving cellulose or wood pulp in a special spinning procedure. It may be blended with linen, cotton, silk, and other fibers to make specialty goods like medical dressings as it is manufactured using non-toxic and organic solvents. It is used to make newborn diapers as well as surgical coats for doctors and nurses. It is also used to improve the appearance of clothes in a range of textile fibers such as cotton, polyester, acrylic, wool, and silk. Lyocell fibers have been demonstrated to exhibit improved antibacterial activity against various bacteria and fungi, indicating that they might be used in therapeutic or hygienic goods. Additionally it is used as a precursor for carbon fiber and in dehumidification sheets. Lyocell fibers are also utilized in the automobile industry for seat coverings, battery separators, and other applications. These are used in a wide range of filtration, including lightweight tea bag and coffee filter papers, industrial and automotive air and liquid filters, and food & beverage high capacity depth filters. Further, the rise in demand from textile industry is predicted to drive the market growth during the forecast period. Lyocell fibers is used in silkier-looking things such as women's apparel and men's formal shirts. It may be combined with a wide range of different fibers, including silk, cotton, rayon, polyester, linen, nylon, and wool. Conveyor belts, specialty papers, and medical dressings are also made from lyocell fibers. However, availability of the substitutes is projected to hinder the lyocell fibers market growth. Lyocell fibers is a semi-synthetic fabric that is commonly used as a substitute for cotton or silk. It shares many properties with other fibers such as cotton, linen, silk, ramie, hemp and viscose rayon (to which it is very closely related chemically). On the contrary, eco-friendly production of lyocell fibers is expected to offer ample growth opportunities for the global lyocell fibers industry. Lyocell fibers is the most environment-friendly fabric. It is derived from organic and renewable sources and processed in a
http://dlvr.it/ScYB69

Global Cannabis Pharmaceuticals Market (2022 to 2027) – Featuring AbbVie, Amyris, Aurora Cannabis and Botanix Pharmaceuticals Among Others – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Cannabis Pharmaceuticals Market (2022-2027) by Brand, Product Type, Distribution Channel, Application, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Cannabis Pharmaceuticals Market is estimated to be USD 1.2 Bn in 2022 and is expected to reach USD 2.82 Bn by 2027, growing at a CAGR of 18.6% Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals. As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding growth and reducing risks. Countries Studied America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas) Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe) Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA) Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific) Competitive Quadrant The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Ansoff Analysis The report presents a detailed Ansoff matrix analysis for the Global Cannabis Pharmaceuticals Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach. The analyst analyses the Global Cannabis Pharmaceuticals Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position. Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth. Why buy this report? The report offers a comprehensive evaluation of the Global Cannabis Pharmaceuticals Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies. The report has been compiled through extensive primary and
http://dlvr.it/ScVfCh

Global Dairy Alternatives Market (2022 to 2031) – Featuring CP Kelco, SunOpta, Organic Valley and Eden Foods Among Others – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Dairy Alternatives Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global dairy alternatives Market. The global dairy alternatives market is expected to grow from $21.03 billion in 2021 to $22.26 billion in 2022 at a compound annual growth rate (CAGR) of 5.9%. The market is expected to grow to $28.02 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. Companies Mentioned Tate & Lyle CP Kelco Inc. SunOpta Inc. The Whitewaves Food Company (US) Organic Valley (US) The Hain Celestial Group (US) Blue Diamond Growers (US) Sunopta (Canada) Archer Daniels Midland Company The Coca-Cola Company PepsiCo Inc. Dohler GmbH Sanitarium Health and Wellbeing Company (Australia) Eden Foods (US) Nutriops S.L. (Spain) Earth's Own Food Company (Canada) Triballat Noyal (France) Valsoia S.P.A (Italy) Dohler GmBh (Germany) Panos Brands LLC (US) Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies. Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market. Understand customers based on the latest market research findings. Benchmark performance against key competitors. Utilize the relationships between key data sets for superior strategizing. Suitable for supporting your internal and external presentations with reliable high quality data and analysis The dairy alternatives market consists of sales of dairy alternative products and related services. Dairy alternatives are food & beverages that are used as a substitute for dairy products. These products are extracted from plants including cereals (rice, oats), legumes (soy), seeds (hemp, flax), nuts (peanuts, almond), and other grains (teff, quinoa). The dairy milk alternatives include soy milk, rice milk, oat milk, coconut milk, and flaxseed milk, cheese substitutes comprise soft cheese and hard cheese, butter alternatives such as nut butter, coconut butter, vegetable oil blends, and cultured vegan butter. The main product types are non-dairy milk, butter, cheese, yogurts, ice cream and Other Product Types. Butter, is yellow-to-white solid emulsion of fat globules, water, and inorganic salts and is produced by churning the cream from cows' milk. The various sources of dairy alternatives are almond, soy, oats, hemp, coconut, rice, and Other Product Types. The dairy alternatives are distributed through supermarkets, health food stores, pharmacies, convenience stores, online stores, and Other Product
http://dlvr.it/ScR3Yd

E-40 and Channel Tres Set to Top Lineup at Emerald Cup Harvest Ball 2022

CALIFORNIA: The brightest minds of cannabis will descend to celebrate the beginning of the journey to the 19th annual Emerald Cup with the 2022 Harvest Ball.  The Emerald Cup is thrilled to announce E-40 and Channel Tres as headliners for the festival, bringing a whole new energy that will electrify the weekend and add an Read the full article...
http://dlvr.it/ScNsMK

Cresco Labs & Columbia Care Announce Planned Divestiture in Three Markets to Sean “Diddy” Combs, Creating the First Minority-Owned, Vertically Integrated Multi-State Cannabis Operator

CHICAGO--(BUSINESS WIRE)--Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), a vertically integrated multi-state operator and the No. 1 U.S. wholesaler of branded cannabis, and Columbia Care (NEO:CCHW) (CSE:CCHW) (OTCQX:CCHWF) (“Columbia Care”), today announced the signing of definitive agreements to divest certain New York, Illinois, and Massachusetts assets (the “Assets”) to an entity owned and controlled by Sean “Diddy” Combs (the “Transaction”). The divestiture of the Assets is required for Cresco to close its previously announced acquisition of Columbia Care (the “Columbia Care Acquisition”). The Transaction is expected to close concurrently with the closing of the Columbia Care Acquisition. Total consideration for the Transaction is an amount up to US$185,000,000 (the “Purchase Price”). The Transaction is Combs’ first investment in cannabis, the fastest growing industry in the U.S., and upon closing, will create the country’s first minority-owned and operated, vertically integrated multi-state operator. This industry-changing transaction is rooted in Cresco’s vision to develop the most responsible, respectable and robust industry possible, and advances Combs’ mission to open new doors in emerging industries for Black entrepreneurs and other diverse founders who are underrepresented and underserved. Throughout his legendary career, Combs has solidified himself as one of the most successful business leaders and cultural icons. Establishing an unrivaled track record for breaking new ground and redefining industries, he has built a portfolio of leading global brands across music, entertainment, spirits, fashion, and media. Combs has also maintained a deep commitment to philanthropy, with a focus on empowerment through education and entrepreneurship, and community activism. These vertically integrated New York, Illinois, and Massachusetts assets provide Combs the ability to grow and manufacture cannabis products; wholesale, and distribute those branded products to licensed dispensaries in major metropolitan areas like New York City, Boston, and Chicago; and operate retail stores in all three states. “Today’s announcement is bigger than the Transaction – and it couldn’t come at a time of greater significance and momentum. We’ve seen executive power exercised to address matters of cannabis injustice, we’re seeing bi-partisan support for elements of federal reform, and we’re seeing some of the largest and most influential states in the country launch cannabis programs prioritizing social responsibility – this announcement adds to that momentum,” said Charles Bachtell, Cresco Labs’ CEO. “For Cresco, the transaction is a major step towards closing the Columbia Care acquisition and our leadership position in one of the largest consumer products categories of the future. For an industry in need of greater diversity of leadership and perspective, the substantial presence of a minority-owned operator in some of the most influential markets in the country being led by one of the most prolific and impactful entrepreneurs of our time is momentous…and incredibly exciting. We’re thrilled to welcome Sean and his team to the industry.” “My mission has always been to create opportunities for Black entrepreneurs in industries where we’ve traditionally been denied access, and this acquisition provides the immediate scale and impact needed to create a more equitable future in
http://dlvr.it/ScDY34

Coda Signature Releases Limited Edition ‘Fourth Season’ Line of Fast-Acting Artisanal Cannabis Truffles

DENVER--(BUSINESS WIRE)--Coda Signature, the cannabis industry’s premier infused chocolatier, today announced its first new infused chocolate truffle line in two years, a reflection of its legacy in edibles with a fresh, modern twist. This limited-edition collection, named “Fourth Season,” comes in three unique flavor combinations of Banana Hazelnut, Raspberry Black Sesame and Yuzu Crème Brûlée. Made in small batches and certain to sell out before year’s end, each fast-acting infused chocolate is hand-made and hand-painted, containing 5mg of THC for a pleasant uplift and 10mg of CBD for enhanced feelings of relaxation and pleasure. “Fourth Season” truffles will be available Nov. 10-17 exclusively at most Native Roots recreational dispensaries in Colorado, and then released to cannabis retailers across the state. “We launched Coda Signature in 2016 with a line of infused, handmade truffles, so this is a bit of a homecoming,” said Lauren Gockley, Co-Founder and VP of Innovation. “With the limited-edition release of these artisanal truffles, we are playing with unexpected flavor notes that complement each other for an exceptional gourmet treat that creates an immersive flavor experience that is fast-acting. We named them the ‘Fourth Season’ in homage to winter’s arrival as well as composer Antonio Vivaldi’s beloved violin concerto series, The Four Seasons.” Retailing for $28 and featuring six truffles, two of each flavor, each “Fourth Season” box contains a total of 30mg THC and 60mg CBD with fast onset. These limited-edition truffles join Coda Signature’s array of award-winning Chocolate Bars, Fruit Notes and Topicals. About Coda Signature Coda Signature creates delightfully crafted cannabis experiences featuring luxury edibles and topicals that complement a well-lived life. The women-led and -operated company sets the standard for world-class quality and accessible luxury, earning prestigious awards in multiple markets for its products. Established in 2016, Coda Signature continues to grow its lines and market reach, delivering consistent cannabinoid dosing and artistically crafted cannabis products for both the medicinal and adult-use markets. Coda Signature products are available in dispensaries across Colorado, with planned expansion into other North American emerging markets. Experience Coda: codasignature.com
http://dlvr.it/Sc9RQv